Thalidomide-O-PEG2-NHS ester

Background Introduction

Thalidomide-O-PEG2-NHS ester is a versatile E3 ligase ligand-linker conjugate designed for targeted protein degradation research, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). This compound consists of a thalidomide derivative, known for binding the cereblon (CRBN) E3 ubiquitin ligase, connected through a biocompatible PEG2 (diethylene glycol) linker to an NHS (N-hydroxysuccinimide) ester reactive group. The presence of the NHS ester allows for highly efficient conjugation to amine groups, facilitating the creation of custom PROTAC molecules.

Mechanism

Thalidomide-O-PEG2-NHS ester functions as a bridge between an E3 ligase and a target protein. The thalidomide moiety selectively binds to the CRBN component of the E3 ubiquitin ligase complex. The PEG2 linker provides spatial flexibility, reducing steric hindrance and improving protein accessibility. The NHS ester reacts with primary amines, such as those present on lysine residues of proteins or small-molecule scaffolds, to form stable amide bonds. This enables the covalent attachment of the E3 ligase ligand to various targeting ligands, supporting the modular assembly of bifunctional PROTAC molecules. Once a PROTAC created with this building block links a target protein to CRBN, it induces ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

Thalidomide-O-PEG2-NHS ester is widely used in the synthesis of PROTAC libraries for drug discovery and targeted protein degradation studies. Its key applications include: 1) Generating CRBN-based PROTACs for selectively degrading disease-related proteins; 2) Functionalizing biomolecules or peptides via conjugation to develop novel chemical biology probes; 3) Facilitating research on E3 ligase substrate specificity and ubiquitin-proteasome system modulation; 4) Exploring next-generation therapeutics for cancer, neurodegeneration, and inflammatory diseases by harnessing targeted protein degradation. This product is an essential building block for researchers developing custom degrader molecules and for accelerating early-stage drug development projects.

• Activated NHS ester allows for rapid and efficient conjugation to amine-containing molecules, streamlining PROTAC assembly.
• PEG2 spacer improves aqueous solubility and flexibility for enhanced CRBN E3 ligase recruitment in PROTAC applications.

The Thalidomide-O-PEG2-NHS ester serves as an essential E3 Ligase Ligand-Linker Conjugate in the development of PROTACs, offering a versatile approach to targeted protein degradation. This conjugate facilitates the precise recruitment of E3 ligases, enhancing the degradation of disease-causing proteins, with detailed descriptions of its linker, ligand, and target protein ligand selection following.

Linker: The PEG2 linker in this molecule is characterized by its moderate length and flexibility, allowing for optimal spatial arrangement between the ligand and the target protein. Its non-cleavable nature ensures stability and sustained interaction within the cellular environment.

Ligand: The ligand component, thalidomide, is a well-established E3 ligase recruiter known for its ability to bind cereblon, a component of the CRL4 E3 ubiquitin ligase complex. Its structural characteristics facilitate the effective hijacking of the ubiquitin-proteasome system for targeted protein degradation.

Reactive Site: The NHS ester group acts as the reactive site for coupling with the target protein ligand. It is recommended to employ amide bond formation reactions, which are efficient and reliable under mild conditions, ensuring successful conjugation with a variety of amine-containing warheads.

Recommended Target Protein Ligand: Compatible warheads for this molecule include those with primary amine groups, such as lysine residues or small molecule inhibitors. These warheads enable the formation of stable covalent bonds with the NHS ester, allowing for broad application in the degradation of diverse protein targets, thereby expanding the utility of PROTAC technology in research settings.